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Abstract
Background: Increasing reports of carbapenem resistant Acinetobacter baumannii infections are of serious
concern. Reliable susceptibility testing results remains a critical issue for the clinical outcome. Automated
systems are increasingly used for species identification and susceptibility testing. This study was organized
to evaluate the accuracies of three widely used automated susceptibility testing methods for testing the
imipenem susceptibilities of A. baumannii isolates, by comparing to the validated test methods.
Methods: Selected 112 clinical isolates of A. baumanii collected between January 2003 and May 2006 were
tested to confirm imipenem susceptibility results. Strains were tested against imipenem by the reference
broth microdilution (BMD), disk diffusion (DD), Etest, BD Phoenix, MicroScan WalkAway and Vitek 2
automated systems. Data were analysed by comparing the results from each test method to those
produced by the reference BMD test.
Results: MicroScan performed true identification of all A. baumannii strains while Vitek 2 unidentified one
strain, Phoenix unidentified two strains and misidentified two strains. Eighty seven of the strains (78%)
were resistant to imipenem by BMD. Etest, Vitek 2 and BD Phoenix produced acceptable error rates when
tested against imipenem. Etest showed the best performance with only two minor errors (1.8%). Vitek 2
produced eight minor errors(7.2%). BD Phoenix produced three major errors (2.8%). DD produced two
very major errors (1.8%) (slightly higher (0.3%) than the acceptable limit) and three major errors (2.7%).
MicroScan showed the worst performance in susceptibility testing with unacceptable error rates; 28 very
major (25%) and 50 minor errors (44.6%).
Conclusion: Reporting errors for A. baumannii against imipenem do exist in susceptibility testing systems.
We suggest clinical laboratories using MicroScan system for routine use should consider using a second,
independent antimicrobial susceptibility testing method to validate imipenem susceptibility. Etest,
whereever available, may be used as an easy method to confirm imipenem susceptibility.
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Background
Acinetobacter baumannii infections mostly affect debili-
tated patients in intensive care units and are associated
with high mortality rates [1,2]. A. baumannii is difficult to
control and treat because of its prolonged environmental
survival and its ability to develop resistance to multiple
antimicrobial agents [3]. Carbapenems are considered the
gold standard treatment for multidrug resistant (MDR) A.
baumannii  infections, imipenem being the most active
agent [1,3]. However, reports of imipenem-resistant A.
baumannii strains have been increasing during the past few
years, and these isolates are often multidrug resistant
MDR [3-7]. Inappropriate antimicrobial treatment
increases mortality in patients with bacteraemia [8]. Reli-
able susceptibility testing results remains a critical issue
for the clinical outcome for these patients.
Automated systems have been increasingly used in many
clinical laboratories for species identification of the bacte-
ria and susceptibility testing. These systems are able to
decrease the labour and in-laboratory time compared to
that required for standardized methods and help the phy-
sicians guide efficient antimicrobial therapy based on
rapid and convenient results [9]. On the other hand, prob-
able errors reported by test system can have serious impli-
cations for the clinical outcome for patients.
Currently MDR Acinetobacters are among the most fre-
quent nosocomial pathogens in our institution. After the
introduction of the MicroScan WalkAway system for sus-
ceptibility testing in 2006, we noted a considerable pro-
portion of discordant results in imipenem susceptibilities
of Acinetobacters compared to disk diffusion results. Upon
this observation, this study was organized to evaluate the
accuracies of three widely used automated susceptibility
testing methods for testing the imipenem susceptibilities
of Acinetobacter baumannii isolates, by comparing to the
validated test methods.
Methods
One hundred twelve non dublicate clinical isolates of A.
baumanii collected between January 2003 and May 2006
were tested to confirm imipenem susceptibility results.
These isolates were selected retrospectively among the
strain collection derived from the clinical samples submit-
ted to the microbiology laboratory for routine diagnostic
procedures. A. baumannii isolates were previously charac-
terized molecularly by PFGE method, and the selected
strains were predominantly representing different A. bau-
mannii genotypes found in this institution including both
epidemic and sporadic clones. This research has been per-
formed with the approval of Zonguldak Karaelmas Uni-
versity, Application and Research Hospital Ethics
Committee. Identification of A. baumannii was performed
according to conventional microbiological methods and
confirmed by API 20 NE (bioMerieux Inc, France) [10].
Strains were tested against imipenem by broth dilution,
disk diffusion, Etest (AB Biodisk, Solna, Sweden) and by
the automated systems BD Phoenix (Becton Dickinson
Diagnostic Systems, Sparks, MD, USA), MicroScan Walk-
Away (Dade Behring INC. West Sacramento, CA, USA)
and Vitek 2 (bioMe'rieux, Marcy l'Étoile, France). The ref-
erence broth microdilution (BMD) test was performed
using in-house prepared panels according to CLSI [11,12].
Imipenem was kindly provided by the manufacturer
(Merck Sharp & Dohme, Madrid, Spain). Ouality control
strains included P. aeruginosa ATCC 27853 and E. coli
ATCC 25922 as recommended by CLSI [11]. Susceptibil-
ity of the isolates to the following antibacterial agents was
tested by disk-diffusion (DD) method using discs (Oxoid,
UK), and interpreted as recommended by CLSI [11]; imi-
penem (IPM, 10 μg), meropenem (MEM, 10 μg), ceftazi-
dime (CAZ, 30 μg), cefepime (FEP, 30 μg), piperacillin
(PRL, 100 μg), cefotaxime (CTX, 30 μg), ciprofloxacin
(CIP, 5 μg), levofloxacin (LEV, 5 μg), gentamicin (CN, 10
μg), tetracyclin (TE, 30 μg), trimethoprim-sulfamethoxa-
zole (SXT, 1.25/23.75 μg). The study was performed in
three laboratories; for MicroScan WalkAway in Zonguldak
Karaelmas University Hospital, Zonguldak, for BD Phoe-
nix in Acibadem Labmed Clinical Laboratory, Istanbul,
and for Vitek2 in bioMe'rieux Laboratory, Istanbul. The
organisms were tested in a blinded fashion in each labo-
ratory according to the procedures recommended by the
manufacturers. All systems were tested with inocula from
the same subculture. In addition to the WalkAway auto-
mated reading, manual readings were performed on all
MicroScan panels and each isolate was tested at least
twice, at different times.
Data were analysed by comparing the results from each
test method to those produced by BMD test.
SPSS (ver. 11.5) programme was used for all calculations.
Kappa tests was used for agreement. If P values less than
0.05 it was accepted statisticaly significant.
Very major errors were considered when an organism was
defined as resistant by the reference method but was cate-
gorized as susceptible with the tested system. Major errors
were defined when an organism found to be susceptible
by the reference method was considered resistant with the
system. Minor errors occurred when an organism was con-
sidered susceptible or resistant either by the reference
microdilution method or with the tested system but inter-
mediate by the other method. An overall category error
rate of < 10% was considered for an acceptable perform-
ance of susceptibility tests, including ≤1.5% of very major
errors and ≤3.0% major errors [13].
Results
MicroScan performed correct identification of all (n =
112) A. baumannii strains while Vitek 2 unidentified oneBMC Infectious Diseases 2009, 9:30 http://www.biomedcentral.com/1471-2334/9/30
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strain, and Phoenix unidentified two strains and misiden-
tified two strains.
The BMD testing showed that 25 (22%) strains were sus-
ceptible to imipenem while 87 (78%) were resistant.
MIC50 and MIC90 for imipenem was 32 μg/ml and 64 μg/
ml respectively. Compared to the BMD results all other
test systems in the study produced errors when A. bauman-
nii was tested against imipenem. Etest showed the best
performance with only two minor error (1.8%). Vitek2
produced eight minor errors(7.2%). BD Phoenix pro-
duced three major errors (2.8%). DD produced two very
major errors (1.8%) and three major errors (2.7%).
MicroScan showed the worst performance in susceptibil-
ity testing with 28 very major errors (25%) and 50 minor
errors (44.6%). The error rates resulted by the three com-
mercial automated systems and two validated methods
are listed in Table 1. When the results were evaluated
upon the acceptable performance criteria for susceptibility
tests; the error rates of BD Phoenix and Vitek2 were in
acceptable limits while MicroScan performed unaccepta-
ble results with high very major and minor error rates in
detecting imipenem susceptibility.
Susceptibility rates of the isolates against the given antibi-
otics; by DD method and the three automated sytems, are
shown in Table 2. Variations in susceptibility rates when
tested by DD and three automated sytems are also dis-
played in the table. Discordant susceptibility rates were
observed mostly in imipenem, meropenem, cefepime and
trimethoprim-sulfamethoxazole.
Numbers of discordances between the results of DD and
the three automated systems in susceptibility testing to
the given antibiotics are exhibited in Table 3. For trimeth-
oprim-sulfamethoxazole susceptibilities; high numbers of
major discordances were displayed between the DD and
all three automated systems and also between the auto-
mated systems. Minor discordances were mostly observed
for meropenem, levofloxacin, cefepime and tetracyc-
lin.between the three automated systems.
Discussion
Treatment of severe nosocomial infections increasingly
depends on carbapenems. Despite the high level resist-
ance in Acinetobacter spp., carbapenems are still considered
as the most active agents [14-17]. On the other hand,
emergence of resistance to carbapenems is of serious con-
cern [3]. Outbreaks of imipenem-resistant Acinetobacter
have been reported worldwide and carbapenem resistance
among A. baumannii can be endemic in certain hospitals
as well [3,18]. Thus, besides the clinical outcome and cost,
reliable susceptibility testing results remains a critical
issue for hospital infection control and surveillance pro-
grams.
Reproducibility, the ability to track results, potential
impact on the workflow and the availability of rapid
results favor the use of automatic systems in the microbi-
ology laboratory [9]. Rapid identification and susceptibil-
ity testing can have a significant impact on the
management of infections, especially those caused by
antibiotic-resistant bacteria. The development of expert
automated systems has allowed an increase both in the
reproducibility and in the reliability of the results. Unfor-
tunately numerous studies have reported errors of various
automated systems when several organism-antimicrobial
combinations tested[9,19-22].
Discrepancies of resistance to imipenem by automated
systems have been described in enteric species, previously
[19,23]. False resistance to imipenem was documented in
Pseudomonas aeruginosa, A. baumanni, Proteus mirabilis
whereas false susceptibility was reported in Klebsiella pneu-
moniae [2,24,25]. It has been shown that false resistance
was due to the imipenem degradation over time, which
resulted false increases in MICs of imipenem [24].
Whereas, false susceptible results by the automated sys-
tems in K. pneumoniae isolates were attributed in part to
low inoculum size [26,27].
Treatment of A. baumannii infections is guided foremost
by in vitro antimicrobial susceptibility assays. Although
Table 1: Types of errors produced when testing imipenem susceptibilities of A. baummanii isolates by three commercial automated 
systems and two validated methods.
No (%) of indicated type of error compared to BMD result
System/method (no. of strains tested) Very major Major Minor Kappa and P values
BD Phoenix (108) 0 3 (2,8) 0 κ = 0.919 P < 0.0001
MicroScan WalkAway (112) 28 (25)a 05 0  ( 4 4 , 6 ) a κ = 0.158 P < 0.0001
Vitek 2 (111) 0 0 8 (7,2) κ = 0.822 P < 0.0001
Etest (112) 0 0 2 (1,8) κ = 0.950 P < 0.0001
Disk diffusion (112) 2 (1,8)a 3 (2,7) 0 κ = 0.870 P < 0.0001
aUnacceptable levels of errorBMC Infectious Diseases 2009, 9:30 http://www.biomedcentral.com/1471-2334/9/30
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the BD Phoenix, MicroScan Walkaway and Vitek are com-
monly used automated test systems in antimicrobial sus-
ceptibility, few studies have been reported for
discrepancies of resistance to imipenem in A. baumannii
[2,28]. It was also supposed that the prediction of resist-
ance in A. baumannii based upon susceptibility assays
might be less certain than for other bacteria [18].
According to our results, it can be stated that, overall, the
Vitek2 and Phoenix system reliably carried out suscepti-
bility testing for imipenem against A. baumanni. The
MicroScan WalkAway system generally failed to accurately
detect imipenem resistance among our collection of car-
bapenem resistant A. baumanni isolates. Up to our knowl-
edge this is the first description of considerable false
susceptibility results to imipenem in A. baumannii by an
automated system.
This study puts forth discordant results between the three
widely used automated susceptibility testing methods for
testing the imipenem susceptibilities of A. baumannii iso-
lates for consideration. According to the fact that the study
was performed in three laboratories; standardization dif-
ficulties might be questioned. However, all systems were
tested with inocula from the same subculture and proce-
dures were performed stringly according to the manufac-
Table 2: Susceptibilities by disk diffusion and three automated sytems against the antibiotics tested
IMP MEM PRL CAZ FEP CTX CIP LEV CN TE SXT
Disk diffusion
Susceptible (%) 21,4 19,6 3,6 3,6 41,1 3,6 14,3 26,8 58 14,3 29,5
Intermediate (%) - - - 1,8 24,1 0,9 8,9 15,2 1,8 4,5 3,6
BD Phoenix
Susceptible (%) 20,4 19,4 1,8 3,7 5,6 - 3,6 25,9 50 14,8 40,7
Intermediate (%) - - 3,6 2,8 50 4,5 19,4 13,9 5,6 11,1 -
MicroScan WalkAway
Susceptible (%) 46,4 22,3 1,8 7,1 11,6 - 4,5 26,8 56,3 18,8 33,9
Intermediate (%) 44,6 23,2 3,6 8,9 50 4,5 9,8 13,4 4,5 3,6 3,6
Vitek 2
Susceptible (%) 22,5 32,4 2,7 3,6 16,2 0,9 4,5 27,9 60,4 24,3 49,5
Intermediate (%) 7,2 64,9 2,7 2,7 45 3,6 3,6 24,3 1,8 7,2 -
Table 3: Correlation of the results of disk diffusion (DD) and automated systems in susceptibility testing to the antibiotics tested: 
Numbers of discordances.
Discordances between DD and the three automated 
systems
Discordances between the three automated systems






Major* Minor** Major* Minor** Major* Minor** Major* Minor** Major* Minor** Major* Minor**
MEM 3 30 7 62 15 72 3 62 4 62 31
PRL 443 1 12
CAZ 33 1 0 132 1 3 1 21 1 3
FEP 94 144 373 411 6 3 1 612 0
CTX 14161412 1 212
CIP 11 77 9 91 4 1 1 1 9 1 5
LEV 12 5 2 412 4 2 1 2 2 1 7
CN 78455315 5 637
TE 5 7 8 5 11 11 3 10 2 18 4 10
SXT 15 70 11 4 23 60 17 13 12
* Discordances were defined as "major" when A. baumannii was found to be susceptible by one method/system and resistant with the other 
method/system.
** Discordances were defined as "minor" when A. baumannii was found to be susceptible or resistant by one method/system and intermediate with 
the other method/system.
*** Imipenem was not included in the table; types of errors in susceptibility testing to imipenem by all systems can be derieved in detail from Table 
1.BMC Infectious Diseases 2009, 9:30 http://www.biomedcentral.com/1471-2334/9/30
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turers recommendations for both inoculum preparation
and technical details at every laboratory. All strains for
which the commercial MIC results were discrepant with
MIC results from the BMD reference method were retested
by using all methods. Besides, the BMD, Etest, DD meth-
ods were performed at the same laboratory with the auto-
mated system which displayed unacceptable error rates.
Although our results clearly displayed that the MicroScan
system failed to accurately detect imipenem resistance
among our A. baumanni isolates; it was not possible to
attribute the invalid MIC results to a certain factor in our
case. Previously it was suggested that the variability in
detecting imipenem resistance by automated systems was
partly a result of underinoculating the panels and was
emphasised that appropriate inoculum size was a critical
factor for achieving accurate results especially when cell
wall-active antimicrobials were tested [19,26]. False-sus-
ceptible results based on these factors were noted with
both VITEK and MicroScan WalkAway systems [26,27].
Based on this data; our initial effort was careful attention
to inoculum. Prompt Inoculation System-D (3 M Com-
pany, St. Paul, MN) is generally used practically for inoc-
ulum preparation in MicroScan systems. We repeated
imipenem susceptibility testing of all discordant isolates
in our study using the MicroScan System, with inocula
prepared using both Prompt Inoculation System-D and
the CLSI recommended protocol. However, repeat testing
of isolates with careful attention to inoculum appeared
not to improve results. On the other hand, the same bac-
terial inoculum prepared per each isolate according to
CLSI was used concurrently for the Etest and BMD and
also retested by the MicroScan WalkAway system, which
gave high error rates. According to our results, it should be
stated that inoculum size, indeed, cannot be attributed to
the inaccurate results in our case.
As recommended by the manufacturer, manual readings
were performed on all MicroScan panels as well. It was
previously noted that MicroScan yielded several very
major errors by the automated instrument readings but
only minor or no errors when the tests were read visu-
ally[23]. The probable reason for manuel reading was
based on the instrument's threshold for identifying bacte-
rial growth [23]. At the same time growth control wells
were also checked on each panel. Technical maintenance
was carried out by the manufacturer's service and a
selected group of the discordant A. baumanni strains was
also tested by the application specialist. Nevertheless
these efforts appeared not to be able to improve the results
performed by MicroScan WalkAway system. Yet we
remain unable to explain the high rate of very major and
minor errors by MicroScan system Speculating other prob-
able reasons; high false sensitivity of A. baumannii to imi-
penem might be due to a higher-than-expected or
inconsistent concentration of imipenem used in the sys-
tem, which remains to be further illuminated by the man-
ufacturer. Improper plates and other probable technical
errors are other issues needs to be addressed. However it
could be noted that our results may only apply under the
circumstances in our laboratory as well as the shipping
conditions during the study.
According to our results; DD method produced an unac-
ceptable rate of very major errors (1.8%), slightly higher
than the acceptable limit (1.5%), that can be reconsidered
accounting the total number of the isolates. In considera-
tion of low cost and requirement of no special equipment;
DD method, available in most laboratories, seems to be a
useful method for susceptibility testing of A. baumannii to
imipenem. However, our data suggest that traditional disk
diffusion method may result in very low rates of very
major errors. Etest method, whereever available, may be
used as an accurate testing method to confirm questiona-
ble results generated by automated methods and DD for
susceptibility testing of A. baumannii to imipenem.
It is noteworthy that; inconsistent results with DD and by
all automated systems in susceptibilities to antibiotics
other than imipenem were also observed in this study;
mainly in susceptibilities to trimethoprim-sulfamethoxa-
zole, meropenem, cefepime and levofloxacin; consecu-
tively. Besides when compared to each other;
discordances between the three automated systems were
also encountered mostly with these antibiotics. Previously
high minor error levels were already noted for automated
systems when testing β-lactam antimicrobials in P. aerugi-
nosa [19,22,23]. However, the accuracy of the automated
systems in susceptibility testing of A. baumannii against
the aforementioned antibiotics should be further evaluted
with other studies by using the reference BMD method.
Conclusion
Testing difficulties in susceptibility testing do exist in
automated susceptibility testing systems. Reporting errors
can have serious implications for the clinical outcome for
patients. We suggest clinical laboratories using MicroScan
automated system for routine use should consider using a
second, independent antimicrobial susceptibility testing
method to validate imipenem susceptibility. Disk diffu-
sion method may result in very low rates of very major
errors. Etest as an easy method may be used to confirm
imipenem susceptibility. If treatment failure with carbap-
enems is observed for isolates of A. baumanni that were
previously reported as susceptible to carbapenems, repeat
testing with a nonautomated method should be war-
ranted.
Competing interests
The authors declare that they have no competing interests.BMC Infectious Diseases 2009, 9:30 http://www.biomedcentral.com/1471-2334/9/30
Page 6 of 7
(page number not for citation purposes)
Authors' contributions
CK conceived the study, and participated in its design,
coordination, carrying out and drafted the manuscript. EA
carried out MIC testing and participated in the design of
the study. FB participated in coordination and the MIC
testing. NO carried out the automated tests and partici-
pated in the design. IA carried out BD Phoenix test. HA
participated in the design of the study and performed the
statistical analysis. All authors read and approved the final
manuscript.
About the authors
Canan Kulah: Ass. Asc. Prof. Dr. of Medical Microbiology
Elif Aktas: Ass. Asc. Prof. Dr. of Medical Microbiology
Fusun Comert: Asc. Prof. Dr. of Medical Microbiology
Nagihan Ozlu: Specialist Dr. in Medical Microbiology
Isin Akyar: Specialist Dr. in Medical Microbiology
Handan Ankarali: Asc. Prof. Dr. of Biostatistics
Acknowledgements
We are grateful to Istanbul bioMe'rieux Laboratory for providing the Vitek 
2 consumables and instruments. We thank Hakan Filizel (Sante Medical 
Istanbul) for providing Phoenix tests and to Dade Behring Istanbul for pro-
viding Etests.
This study was partly presented as a poster at the European Congress of 
Clinical Microbiology and Infectious Diseases (ECCMID) 2008, Barcelona.
References
1. Bergogne-Berezin E, Towner KJ: Acinetobacter spp. as nosoco-
mial pathogens: microbiological, clinical, and epidemiologi-
cal features.  Clin Microbiol Rev 1996, 9:148-165.
2. Tsakris A, Pantazi A, Pournaras S, Maniatis A, Polyzou A, Sofianou D:
Pseudo-outbreak of imipenem-resistant Acinetobacter bau-
mannii resulting from false susceptibility testing by a rapid
automated system.  J Clin Microbiol 2000, 38(9):3505-7.
3. Poirel L, Nordmann P: Carbapenem resistance in Acinetobacter
baumannii: mechanisms and epidemiology.  Clin Microbiol Infect
2006, 12(9):826-836.
4. Bou G, Cervero G, Dominguez MA, Quereda C, Martinez-Beltran J:
PCR-based DNA fingerprinting (REP-PCR, AP-PCR) and
pulsed-field gel electrophoresis characterization of a nosoco-
mial outbreak caused by imipenem- and meropenem-resist-
ant  Acinetobacter baumannii.  Clin Microbiol Infect 2000,
6(12):635-43.
5. Corbella X, Montero A, Pujol M, Domínguez MA, Ayats J, Argerich
MJ, Garrigosa F, Ariza J, Gudiol F: Emergence and rapid spread of
carbapenem resistance during a large and sustained hospital
outbreak of multiresistant Acinetobacter baumannii.  J Clin
Microbiol 2000, 38(11):4086-95.
6. He'ritier C, Dubouix A, Poirel L, Marty N, Nordmann P: A nosoco-
mial outbreak of Acinetobacter baumannii isolates expressing
the carbapenem-hydrolysing oxacillinase OXA-58.  J Antimi-
crob Chemother 2005, 55:115-118.
7. Pournaras S, Markogiannakis A, Ikonomidis A, Kondyli L, Bethimouti
K, Maniatis AN, Legakis NJ, Tsakris A: Outbreak of multiple
clones of imipenem-resistant Acinetobacter baumannii iso-
lates expressing OXA-58 carbapenemase in an intensive
care unit.  J Antimicrob Chemother 2006, 57:557-561.
8. Cisneros JM, Reyes MJ, Pachon J, Becerril B, Caballero FJ, García-Gar-
mendía JL, Ortiz C, Cobacho AR: Bacteremia due to Acineto-
bacter baumannii: epidemiology, clinical and prognostic
features.  Clin Infect Dis 1996, 22:1026-1032.
9. Donay JL, Mathieu D, Fernandes P, Prégermain C, Bruel P, Wargnier
A, Casin I, Weill FX, Lagrange PH, Herrmann JL: Evaluation of the
automated Phoenix system for potential routine use in the
clinical microbiology laboratory.  J Clin Microbiol 2004,
42(4):1542-6.
10. Schreckenberger PC, Daneshvar MI, Weyant RS, Hollis DG: Acineto-
bacter,  Achromobacter,  Chryseobacterium,  Moraxella, and
other nonfermentative gram-negative rods.  In Manual of Clini-
cal Microbiology Edited by: Murray PR, Baron EJ, Jorgensen JH, Pfaller
MA, Yolken RH. Washington (DC): ASM Pres; 2003:749-779. 
11. Clinical and Laboratory Standards Institute: Approved standart
M100-S16. Performance standards for antimicrobial suscep-
tibility testing.  Clinical and Laboratory Standards Institute, Wayne,
Pennsylvania, USA; 2006. 
12. Clinical and Laboratory Standards Institute: Approved Standart
M7-A6. Methods for dilution antimicrobial susceptibility
tests for bacteria that growth aerobically.  6th edition. Clinical
and Laboratory Standards Institute, Wayne, Pennsylvania, USA; 2005. 
13. National Committee for Clinical Laboratory Standards: Approved
guideline M23-A2. Development of in vitro susceptibility
testing criteria and quality control parameters.  2nd edition.
National Committee for Clinical Laboratory Standards, Wayne, Penn-
sylvania, USA; 2001. 
14. Goossens H: MYSTIC (Meropenem Yearly Susceptibility Test
Information Collection) results from Europe: comparison of
antibiotic susceptibilities between countries and centre
types. MYSTIC Study Group (European centres only).  J Anti-
microb Chemother 2000, 46(Supp 2):39-52.
15. Jones RN, Mendes C, Turner PJ, Masterton R: An overview of the
Meropenem Yearly Susceptibility Test Information Collec-
tion (MYSTIC) Program: 1997–2004.  Diagn Microbiol Infect Dis
2005, 53:247-256.
16. Korten V, Ulusoy S, Zarakolu P, Mete B: Turkish MYSTIC Study
Group. Antibiotic resistance surveillance over a 4-year
period (2000–2003) in Turkey: results of the MYSTIC Pro-
gram.  Diagn Microbiol Infect Dis 2007, 59(4):453-7.
17. Eraksoy H, Basustaoglu A, Korten V, Kurt H, Ozturk R, Ulusoy S,
Yaman A, Yuce A, Zarakolu P, Turkish MYSTIC Study Group: Sus-
ceptibility of bacterial isolates from Turkey – a report from
the Meropenem Yearly Susceptibility Test Information Col-
lection (MYSTIC) Program.  J Chemother 2007, 19(6):650-7.
18. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA:
Global challenge of multidrug-resistant Acinetobacter bau-
mannii.  Antimicrob Agents Chemother 2007, 51(10):3471-84.
19. Doern GV, Brueggemann AB, Perla R, Daly J, Halkias D, Jones RN,
Saubolle MA: Multicenter laboratory evaluation of the
bioMérieux Vitek antimicrobial susceptibility testing system
with 11 antimicrobial agents versus members of the family
Enterobacteriaceae and Pseudomonas aeruginosa.  J Clin Microbiol
1997, 35(8):2115-2119.
20. Biedenbach DJ, Jones RN: Interpretive errors using an auto-
mated system for the susceptibility testing of imipenem and
aztreonam.  Diagn Microbiol Infect Dis 1995, 21:57-60.
21. Marshall SA: Serious interpretive error among three commer-
cial systems for susceptibility testing of aztreonam. Aztre-
onam Study Group.  Diagn Microbiol Infect Dis 1995, 22(3):249-51.
22. Sader HS, Fritsche TR, Jones RN: Accuracy of three automated
systems (MicroScan WalkAway, VITEK, and VITEK 2) for
susceptibility testing of Pseudomonas aeruginosa against five
broad-spectrum beta-lactam agents.  J Clin Microbiol 2006,
44(3):1101-4.
23. Steward CD, Mohammed JM, Swenson JM, Stocker SA, Williams PP,
Gaynes RP, et al.: Antimicrobial susceptibility testing of car-
bapenems: multicenter validity testing and accuracy levels of
five antimicrobial test methods for detecting resistance in
Enterobacteriaceae and Pseudomonas aeruginosa isolates.  J
Clin Microbiol 2003, 41:351-8.
24. White RL, Kays MB, Friedrich LV, Brown EW, Koonce JR: Pseudor-
esistance of Pseudomonas aeruginosa resulting from degrada-
tion of imipenem in an automated susceptibility testing
system with predried panels.  J Clin Microbiol 1991, 29:398-400.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Infectious Diseases 2009, 9:30 http://www.biomedcentral.com/1471-2334/9/30
Page 7 of 7
(page number not for citation purposes)
25. Tenover FC, Kalsi RK, Williams PP, Carey RB, Stocker S, Lonsway D,
Rasheed JK, Biddle JW, McGowan JE Jr, Hanna B: Carbapenem
resistance in Klebsiella pneumoniae not detected by auto-
mated susceptibility testing.  Emerg Infect Dis 2006,
12(8):1209-13.
26. Bratu S, Mooty M, Nichani S, Landman D, Gullans C, Pettinato B,
Karumudi U, Tolaney P, Quale J: Emergence of KPC-possessing
Klebsiella pneumoniae in Brooklyn, New York: epidemiology
and recommendations for detection.  Antimicrob Agents Chem-
other 2005, 49:3018-20.
27. Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M, Quale J:
Rapid spread of carbapenem-resistant Klebsiella pneumoniae
in New York City: a new threat to our antibiotic armamen-
tarium.  Arch Intern Med 2005, 165:1430-5.
28. Endimiani A, Luzzaro F, Tamborini A, Lombardi G, Elia V, Belloni R,
Toniolo A: Identification and antimicrobial susceptibility test-
ing of clinical isolates of nonfermenting gram-negative bac-
teria by the Phoenix Automated Microbiology System.  New
Microbiol 2002, 25(3):323-9.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2334/9/30/prepub